Global Oral Anti-Diabetic Drug Supply, Demand and Key Producers, 2026-2032
The global Oral Anti-Diabetic Drug market size is expected to reach $ 68304 million by 2032, rising at a market growth of 5.0% CAGR during the forecast period (2026-2032).
Oral anti-diabetes drugs are orally administered medications used primarily for the treatment of diabetes, especially type 2 diabetes, aiming to control hyperglycemia through diverse mechanisms such as enhancing insulin secretion, improving insulin sensitivity, reducing hepatic glucose production, delaying carbohydrate absorption, or increasing urinary glucose excretion. Compared with injectables, oral therapies generally offer greater convenience and support long-term adherence, making them suitable across the treatment continuum?from initial therapy to multi-drug combination regimens. Historically, modern oral glucose-lowering therapy took shape in the mid-20th century with sulfonylureas and biguanides as foundational classes; subsequent decades introduced additional targets including alpha-glucosidase inhibitors and thiazolidinediones. In the 21st century, innovation accelerated with DPP-4 inhibitors and SGLT2 inhibitors, shifting the focus from glucose reduction alone toward broader outcomes such as cardio-renal protection, weight considerations, and individualized treatment strategies; more recently, oral GLP-1 receptor agonists have further advanced the drive for convenience alongside metabolic benefits. Upstream, the supply chain typically consists of active pharmaceutical ingredients (APIs) and formulation excipients: API manufacturing relies on commodity and fine-chemical inputs (basic chemical feedstocks, solvents, catalysts, chiral intermediates, and specialty reagents), while the finished dosage form requires functional excipients (fillers, binders, disintegrants, lubricants, film-coating materials, and modified-release polymers). It also depends on pharmaceutical packaging materials (aluminum foil, PVC/PVDC blister films, HDPE bottles, desiccants, seals, labels, and cartons) and supporting manufacturing equipment and key components (granulation, tableting, coating, capsule filling, in-line inspection, HVAC/cleanroom systems, and purified-water utilities) to ensure stability, bioavailability, and consistent large-scale production.In 2025, the global production capacity of oral anti-diabetes drugs is estimated to be approximately 6?8 billion boxes. Sales volume is projected to reach 4.96 billion boxes, with an average selling price of about USD 9.5 per box. Industry gross margins are expected to range between 35% and 50%.
The oral anti-diabetes drug market today is characterized by an upgrading of treatment goals, a clear split in product mix across segments, and pronounced differences in access and affordability by region. Prescribing decisions increasingly prioritize comorbidity management and long-term outcomes, which strengthens demand for oral therapies associated with cardio-renal benefits, weight-friendly profiles, and low hypoglycemia risk. At the same time, established oral agents remain the backbone in many countries, particularly where budget constraints are tighter and out-of-pocket payment is higher, because they offer stable supply and lower overall treatment cost. Competition is also shifting from molecule-to-molecule battles toward regimen-level competition: fixed-dose combinations, stepwise treatment algorithms, and chronic-care support (refill continuity, adherence reminders, follow-up) are becoming part of the value proposition. On the supply side, scale, quality consistency, and compliance capabilities in API and finished-dose manufacturing increasingly determine whether a company can participate in major procurement channels and international markets.
Looking ahead, the market trajectory will be shaped by oral innovation, combination strategies, and full-course disease management. As clinical evidence expands across drug classes, prescribing will become more stratified?tailored to cardiovascular risk, kidney function, weight considerations, and hypoglycemia avoidance?supporting earlier-line adoption of innovative oral options and sustained momentum for differentiated formulations and combinations. Advances in oral delivery and formulation science may further broaden the ?oralization? frontier for peptide-like therapies, improving patient acceptance and redefining competitive boundaries. In parallel, digital health and the growing role of retail and e-pharmacy refills will accelerate the transition from ?selling pills? to ?delivering therapy services,? where real-world evidence, adherence programs, and outcomes-based reimbursement arrangements influence market access and investment priorities. Meanwhile, local supply chain build-out and quality-system upgrades in multiple regions will enable more regional players to compete in higher-value oral segments, creating a more layered and dynamic global competitive landscape.
Growth drivers and constraints will continue to coexist, with the balance often determined by reimbursement and regulatory settings, evidence thresholds, and supply-chain resilience. Key tailwinds include the rising burden of diabetes, guideline-driven treatment upgrading, payer emphasis on reducing cardio-renal events and hospitalization risk, and improved adherence enabled by convenient oral regimens; patent expiries and generic substitution will also create recurring ?price-for-volume? opportunities across mature categories. Headwinds include cost-containment policies and centralized purchasing that compress pricing and margins, forcing companies to compete on efficiency and differentiated evidence; higher safety and long-term outcomes expectations that raise R&D and access barriers; and potential disruptions from API price volatility, quality incidents, and cross-border compliance requirements. Overall, sustainable winners are likely to be those that balance strong clinical evidence, a differentiated portfolio strategy, affordability/access planning, and a robust, compliant supply chain.
This report studies the global Oral Anti-Diabetic Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oral Anti-Diabetic Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oral Anti-Diabetic Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oral Anti-Diabetic Drug total production and demand, 2021-2032, (K Units)
Global Oral Anti-Diabetic Drug total production value, 2021-2032, (USD Million)
Global Oral Anti-Diabetic Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Oral Anti-Diabetic Drug consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Oral Anti-Diabetic Drug domestic production, consumption, key domestic manufacturers and share
Global Oral Anti-Diabetic Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Oral Anti-Diabetic Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Oral Anti-Diabetic Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Oral Anti-Diabetic Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Merck, Novartis, Johnson & Johnson, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Viatris, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oral Anti-Diabetic Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Oral Anti-Diabetic Drug Market, By Region:
1. How big is the global Oral Anti-Diabetic Drug market?
2. What is the demand of the global Oral Anti-Diabetic Drug market?
3. What is the year over year growth of the global Oral Anti-Diabetic Drug market?
4. What is the production and production value of the global Oral Anti-Diabetic Drug market?
5. Who are the key producers in the global Oral Anti-Diabetic Drug market?
6. What are the growth factors driving the market demand?
Oral anti-diabetes drugs are orally administered medications used primarily for the treatment of diabetes, especially type 2 diabetes, aiming to control hyperglycemia through diverse mechanisms such as enhancing insulin secretion, improving insulin sensitivity, reducing hepatic glucose production, delaying carbohydrate absorption, or increasing urinary glucose excretion. Compared with injectables, oral therapies generally offer greater convenience and support long-term adherence, making them suitable across the treatment continuum?from initial therapy to multi-drug combination regimens. Historically, modern oral glucose-lowering therapy took shape in the mid-20th century with sulfonylureas and biguanides as foundational classes; subsequent decades introduced additional targets including alpha-glucosidase inhibitors and thiazolidinediones. In the 21st century, innovation accelerated with DPP-4 inhibitors and SGLT2 inhibitors, shifting the focus from glucose reduction alone toward broader outcomes such as cardio-renal protection, weight considerations, and individualized treatment strategies; more recently, oral GLP-1 receptor agonists have further advanced the drive for convenience alongside metabolic benefits. Upstream, the supply chain typically consists of active pharmaceutical ingredients (APIs) and formulation excipients: API manufacturing relies on commodity and fine-chemical inputs (basic chemical feedstocks, solvents, catalysts, chiral intermediates, and specialty reagents), while the finished dosage form requires functional excipients (fillers, binders, disintegrants, lubricants, film-coating materials, and modified-release polymers). It also depends on pharmaceutical packaging materials (aluminum foil, PVC/PVDC blister films, HDPE bottles, desiccants, seals, labels, and cartons) and supporting manufacturing equipment and key components (granulation, tableting, coating, capsule filling, in-line inspection, HVAC/cleanroom systems, and purified-water utilities) to ensure stability, bioavailability, and consistent large-scale production.In 2025, the global production capacity of oral anti-diabetes drugs is estimated to be approximately 6?8 billion boxes. Sales volume is projected to reach 4.96 billion boxes, with an average selling price of about USD 9.5 per box. Industry gross margins are expected to range between 35% and 50%.
The oral anti-diabetes drug market today is characterized by an upgrading of treatment goals, a clear split in product mix across segments, and pronounced differences in access and affordability by region. Prescribing decisions increasingly prioritize comorbidity management and long-term outcomes, which strengthens demand for oral therapies associated with cardio-renal benefits, weight-friendly profiles, and low hypoglycemia risk. At the same time, established oral agents remain the backbone in many countries, particularly where budget constraints are tighter and out-of-pocket payment is higher, because they offer stable supply and lower overall treatment cost. Competition is also shifting from molecule-to-molecule battles toward regimen-level competition: fixed-dose combinations, stepwise treatment algorithms, and chronic-care support (refill continuity, adherence reminders, follow-up) are becoming part of the value proposition. On the supply side, scale, quality consistency, and compliance capabilities in API and finished-dose manufacturing increasingly determine whether a company can participate in major procurement channels and international markets.
Looking ahead, the market trajectory will be shaped by oral innovation, combination strategies, and full-course disease management. As clinical evidence expands across drug classes, prescribing will become more stratified?tailored to cardiovascular risk, kidney function, weight considerations, and hypoglycemia avoidance?supporting earlier-line adoption of innovative oral options and sustained momentum for differentiated formulations and combinations. Advances in oral delivery and formulation science may further broaden the ?oralization? frontier for peptide-like therapies, improving patient acceptance and redefining competitive boundaries. In parallel, digital health and the growing role of retail and e-pharmacy refills will accelerate the transition from ?selling pills? to ?delivering therapy services,? where real-world evidence, adherence programs, and outcomes-based reimbursement arrangements influence market access and investment priorities. Meanwhile, local supply chain build-out and quality-system upgrades in multiple regions will enable more regional players to compete in higher-value oral segments, creating a more layered and dynamic global competitive landscape.
Growth drivers and constraints will continue to coexist, with the balance often determined by reimbursement and regulatory settings, evidence thresholds, and supply-chain resilience. Key tailwinds include the rising burden of diabetes, guideline-driven treatment upgrading, payer emphasis on reducing cardio-renal events and hospitalization risk, and improved adherence enabled by convenient oral regimens; patent expiries and generic substitution will also create recurring ?price-for-volume? opportunities across mature categories. Headwinds include cost-containment policies and centralized purchasing that compress pricing and margins, forcing companies to compete on efficiency and differentiated evidence; higher safety and long-term outcomes expectations that raise R&D and access barriers; and potential disruptions from API price volatility, quality incidents, and cross-border compliance requirements. Overall, sustainable winners are likely to be those that balance strong clinical evidence, a differentiated portfolio strategy, affordability/access planning, and a robust, compliant supply chain.
This report studies the global Oral Anti-Diabetic Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oral Anti-Diabetic Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oral Anti-Diabetic Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oral Anti-Diabetic Drug total production and demand, 2021-2032, (K Units)
Global Oral Anti-Diabetic Drug total production value, 2021-2032, (USD Million)
Global Oral Anti-Diabetic Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Oral Anti-Diabetic Drug consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Oral Anti-Diabetic Drug domestic production, consumption, key domestic manufacturers and share
Global Oral Anti-Diabetic Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Oral Anti-Diabetic Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Oral Anti-Diabetic Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Oral Anti-Diabetic Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Merck, Novartis, Johnson & Johnson, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Viatris, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oral Anti-Diabetic Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Oral Anti-Diabetic Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- SGLT2 Inhibitors
- DPP-4 Inhibitors
- Biguanides
- Sulfonylureas
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- Meglitinides
- Innovative Patented Drugs
- Patent-Expired Branded Drugs
- Generic Drugs
- First-Line Therapy
- Second-Line Add-On
- Third-Line / Rescue Therapy
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly and Company
- Novo Nordisk
- Merck
- Novartis
- Johnson & Johnson
- Takeda Pharmaceutical Company
- Teva Pharmaceutical Industries
- Viatris
- Sandoz
- Sun Pharmaceutical Industries
- Dr. Reddy's Laboratories
- Aurobindo Pharma
- Lupin Limited
- Cipla
- Torrent Pharmaceuticals
- Zydus Lifesciences
- Abbott
- Mankind Pharma
- Tonghua Dongbao
- Huadong Medicine
- CSPC Pharmaceutical Group
- Fosun Pharma
- Qilu Pharmaceutical
1. How big is the global Oral Anti-Diabetic Drug market?
2. What is the demand of the global Oral Anti-Diabetic Drug market?
3. What is the year over year growth of the global Oral Anti-Diabetic Drug market?
4. What is the production and production value of the global Oral Anti-Diabetic Drug market?
5. Who are the key producers in the global Oral Anti-Diabetic Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Oral Anti-Diabetic Drug Introduction
1.2 World Oral Anti-Diabetic Drug Supply & Forecast
1.2.1 World Oral Anti-Diabetic Drug Production Value (2021 & 2025 & 2032)
1.2.2 World Oral Anti-Diabetic Drug Production (2021-2032)
1.2.3 World Oral Anti-Diabetic Drug Pricing Trends (2021-2032)
1.3 World Oral Anti-Diabetic Drug Production by Region (Based on Production Site)
1.3.1 World Oral Anti-Diabetic Drug Production Value by Region (2021-2032)
1.3.2 World Oral Anti-Diabetic Drug Production by Region (2021-2032)
1.3.3 World Oral Anti-Diabetic Drug Average Price by Region (2021-2032)
1.3.4 North America Oral Anti-Diabetic Drug Production (2021-2032)
1.3.5 Europe Oral Anti-Diabetic Drug Production (2021-2032)
1.3.6 China Oral Anti-Diabetic Drug Production (2021-2032)
1.3.7 Japan Oral Anti-Diabetic Drug Production (2021-2032)
1.3.8 India Oral Anti-Diabetic Drug Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oral Anti-Diabetic Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Oral Anti-Diabetic Drug Major Market Trends
2 DEMAND SUMMARY
2.1 World Oral Anti-Diabetic Drug Demand (2021-2032)
2.2 World Oral Anti-Diabetic Drug Consumption by Region
2.2.1 World Oral Anti-Diabetic Drug Consumption by Region (2021-2026)
2.2.2 World Oral Anti-Diabetic Drug Consumption Forecast by Region (2027-2032)
2.3 United States Oral Anti-Diabetic Drug Consumption (2021-2032)
2.4 China Oral Anti-Diabetic Drug Consumption (2021-2032)
2.5 Europe Oral Anti-Diabetic Drug Consumption (2021-2032)
2.6 Japan Oral Anti-Diabetic Drug Consumption (2021-2032)
2.7 South Korea Oral Anti-Diabetic Drug Consumption (2021-2032)
2.8 ASEAN Oral Anti-Diabetic Drug Consumption (2021-2032)
2.9 India Oral Anti-Diabetic Drug Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Oral Anti-Diabetic Drug Production Value by Manufacturer (2021-2026)
3.2 World Oral Anti-Diabetic Drug Production by Manufacturer (2021-2026)
3.3 World Oral Anti-Diabetic Drug Average Price by Manufacturer (2021-2026)
3.4 Oral Anti-Diabetic Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Oral Anti-Diabetic Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Oral Anti-Diabetic Drug in 2025
3.5.3 Global Concentration Ratios (CR8) for Oral Anti-Diabetic Drug in 2025
3.6 Oral Anti-Diabetic Drug Market: Overall Company Footprint Analysis
3.6.1 Oral Anti-Diabetic Drug Market: Region Footprint
3.6.2 Oral Anti-Diabetic Drug Market: Company Product Type Footprint
3.6.3 Oral Anti-Diabetic Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Oral Anti-Diabetic Drug Production Value Comparison
4.1.1 United States VS China: Oral Anti-Diabetic Drug Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Oral Anti-Diabetic Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Oral Anti-Diabetic Drug Production Comparison
4.2.1 United States VS China: Oral Anti-Diabetic Drug Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Oral Anti-Diabetic Drug Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Oral Anti-Diabetic Drug Consumption Comparison
4.3.1 United States VS China: Oral Anti-Diabetic Drug Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Oral Anti-Diabetic Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Oral Anti-Diabetic Drug Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Oral Anti-Diabetic Drug Production Value (2021-2026)
4.4.3 United States Based Manufacturers Oral Anti-Diabetic Drug Production (2021-2026)
4.5 China Based Oral Anti-Diabetic Drug Manufacturers and Market Share
4.5.1 China Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Oral Anti-Diabetic Drug Production Value (2021-2026)
4.5.3 China Based Manufacturers Oral Anti-Diabetic Drug Production (2021-2026)
4.6 Rest of World Based Oral Anti-Diabetic Drug Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Oral Anti-Diabetic Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 SGLT2 Inhibitors
5.2.2 DPP-4 Inhibitors
5.2.3 Biguanides
5.2.4 Sulfonylureas
5.2.5 Thiazolidinediones
5.2.6 Alpha-Glucosidase Inhibitors
5.2.7 Meglitinides
5.3 Market Segment by Type
5.3.1 World Oral Anti-Diabetic Drug Production by Type (2021-2032)
5.3.2 World Oral Anti-Diabetic Drug Production Value by Type (2021-2032)
5.3.3 World Oral Anti-Diabetic Drug Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY INNOVATION STATUS
6.1 World Oral Anti-Diabetic Drug Market Size Overview by Innovation Status: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Innovation Status
6.2.1 Innovative Patented Drugs
6.2.2 Patent-Expired Branded Drugs
6.2.3 Generic Drugs
6.3 Market Segment by Innovation Status
6.3.1 World Oral Anti-Diabetic Drug Production by Innovation Status (2021-2032)
6.3.2 World Oral Anti-Diabetic Drug Production Value by Innovation Status (2021-2032)
6.3.3 World Oral Anti-Diabetic Drug Average Price by Innovation Status (2021-2032)
7 MARKET ANALYSIS BY GUIDELINE POSITION
7.1 World Oral Anti-Diabetic Drug Market Size Overview by Guideline Position: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Guideline Position
7.2.1 First-Line Therapy
7.2.2 Second-Line Add-On
7.2.3 Third-Line / Rescue Therapy
7.3 Market Segment by Guideline Position
7.3.1 World Oral Anti-Diabetic Drug Production by Guideline Position (2021-2032)
7.3.2 World Oral Anti-Diabetic Drug Production Value by Guideline Position (2021-2032)
7.3.3 World Oral Anti-Diabetic Drug Average Price by Guideline Position (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Oral Anti-Diabetic Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital Pharmacies
8.2.2 Retail Pharmacies
8.2.3 Online Pharmacies
8.3 Market Segment by Application
8.3.1 World Oral Anti-Diabetic Drug Production by Application (2021-2032)
8.3.2 World Oral Anti-Diabetic Drug Production Value by Application (2021-2032)
8.3.3 World Oral Anti-Diabetic Drug Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 AstraZeneca
9.1.1 AstraZeneca Details
9.1.2 AstraZeneca Major Business
9.1.3 AstraZeneca Oral Anti-Diabetic Drug Product and Services
9.1.4 AstraZeneca Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 AstraZeneca Recent Developments/Updates
9.1.6 AstraZeneca Competitive Strengths & Weaknesses
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Details
9.2.2 Boehringer Ingelheim Major Business
9.2.3 Boehringer Ingelheim Oral Anti-Diabetic Drug Product and Services
9.2.4 Boehringer Ingelheim Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Boehringer Ingelheim Recent Developments/Updates
9.2.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.3 Eli Lilly and Company
9.3.1 Eli Lilly and Company Details
9.3.2 Eli Lilly and Company Major Business
9.3.3 Eli Lilly and Company Oral Anti-Diabetic Drug Product and Services
9.3.4 Eli Lilly and Company Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Eli Lilly and Company Recent Developments/Updates
9.3.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.4 Novo Nordisk
9.4.1 Novo Nordisk Details
9.4.2 Novo Nordisk Major Business
9.4.3 Novo Nordisk Oral Anti-Diabetic Drug Product and Services
9.4.4 Novo Nordisk Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Novo Nordisk Recent Developments/Updates
9.4.6 Novo Nordisk Competitive Strengths & Weaknesses
9.5 Merck
9.5.1 Merck Details
9.5.2 Merck Major Business
9.5.3 Merck Oral Anti-Diabetic Drug Product and Services
9.5.4 Merck Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Merck Recent Developments/Updates
9.5.6 Merck Competitive Strengths & Weaknesses
9.6 Novartis
9.6.1 Novartis Details
9.6.2 Novartis Major Business
9.6.3 Novartis Oral Anti-Diabetic Drug Product and Services
9.6.4 Novartis Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Novartis Recent Developments/Updates
9.6.6 Novartis Competitive Strengths & Weaknesses
9.7 Johnson & Johnson
9.7.1 Johnson & Johnson Details
9.7.2 Johnson & Johnson Major Business
9.7.3 Johnson & Johnson Oral Anti-Diabetic Drug Product and Services
9.7.4 Johnson & Johnson Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Johnson & Johnson Recent Developments/Updates
9.7.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.8 Takeda Pharmaceutical Company
9.8.1 Takeda Pharmaceutical Company Details
9.8.2 Takeda Pharmaceutical Company Major Business
9.8.3 Takeda Pharmaceutical Company Oral Anti-Diabetic Drug Product and Services
9.8.4 Takeda Pharmaceutical Company Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Takeda Pharmaceutical Company Recent Developments/Updates
9.8.6 Takeda Pharmaceutical Company Competitive Strengths & Weaknesses
9.9 Teva Pharmaceutical Industries
9.9.1 Teva Pharmaceutical Industries Details
9.9.2 Teva Pharmaceutical Industries Major Business
9.9.3 Teva Pharmaceutical Industries Oral Anti-Diabetic Drug Product and Services
9.9.4 Teva Pharmaceutical Industries Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Teva Pharmaceutical Industries Recent Developments/Updates
9.9.6 Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
9.10 Viatris
9.10.1 Viatris Details
9.10.2 Viatris Major Business
9.10.3 Viatris Oral Anti-Diabetic Drug Product and Services
9.10.4 Viatris Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Viatris Recent Developments/Updates
9.10.6 Viatris Competitive Strengths & Weaknesses
9.11 Sandoz
9.11.1 Sandoz Details
9.11.2 Sandoz Major Business
9.11.3 Sandoz Oral Anti-Diabetic Drug Product and Services
9.11.4 Sandoz Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Sandoz Recent Developments/Updates
9.11.6 Sandoz Competitive Strengths & Weaknesses
9.12 Sun Pharmaceutical Industries
9.12.1 Sun Pharmaceutical Industries Details
9.12.2 Sun Pharmaceutical Industries Major Business
9.12.3 Sun Pharmaceutical Industries Oral Anti-Diabetic Drug Product and Services
9.12.4 Sun Pharmaceutical Industries Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Sun Pharmaceutical Industries Recent Developments/Updates
9.12.6 Sun Pharmaceutical Industries Competitive Strengths & Weaknesses
9.13 Dr. Reddy's Laboratories
9.13.1 Dr. Reddy's Laboratories Details
9.13.2 Dr. Reddy's Laboratories Major Business
9.13.3 Dr. Reddy's Laboratories Oral Anti-Diabetic Drug Product and Services
9.13.4 Dr. Reddy's Laboratories Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Dr. Reddy's Laboratories Recent Developments/Updates
9.13.6 Dr. Reddy's Laboratories Competitive Strengths & Weaknesses
9.14 Aurobindo Pharma
9.14.1 Aurobindo Pharma Details
9.14.2 Aurobindo Pharma Major Business
9.14.3 Aurobindo Pharma Oral Anti-Diabetic Drug Product and Services
9.14.4 Aurobindo Pharma Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Aurobindo Pharma Recent Developments/Updates
9.14.6 Aurobindo Pharma Competitive Strengths & Weaknesses
9.15 Lupin Limited
9.15.1 Lupin Limited Details
9.15.2 Lupin Limited Major Business
9.15.3 Lupin Limited Oral Anti-Diabetic Drug Product and Services
9.15.4 Lupin Limited Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Lupin Limited Recent Developments/Updates
9.15.6 Lupin Limited Competitive Strengths & Weaknesses
9.16 Cipla
9.16.1 Cipla Details
9.16.2 Cipla Major Business
9.16.3 Cipla Oral Anti-Diabetic Drug Product and Services
9.16.4 Cipla Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Cipla Recent Developments/Updates
9.16.6 Cipla Competitive Strengths & Weaknesses
9.17 Torrent Pharmaceuticals
9.17.1 Torrent Pharmaceuticals Details
9.17.2 Torrent Pharmaceuticals Major Business
9.17.3 Torrent Pharmaceuticals Oral Anti-Diabetic Drug Product and Services
9.17.4 Torrent Pharmaceuticals Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 Torrent Pharmaceuticals Recent Developments/Updates
9.17.6 Torrent Pharmaceuticals Competitive Strengths & Weaknesses
9.18 Zydus Lifesciences
9.18.1 Zydus Lifesciences Details
9.18.2 Zydus Lifesciences Major Business
9.18.3 Zydus Lifesciences Oral Anti-Diabetic Drug Product and Services
9.18.4 Zydus Lifesciences Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Zydus Lifesciences Recent Developments/Updates
9.18.6 Zydus Lifesciences Competitive Strengths & Weaknesses
9.19 Abbott
9.19.1 Abbott Details
9.19.2 Abbott Major Business
9.19.3 Abbott Oral Anti-Diabetic Drug Product and Services
9.19.4 Abbott Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.19.5 Abbott Recent Developments/Updates
9.19.6 Abbott Competitive Strengths & Weaknesses
9.20 Mankind Pharma
9.20.1 Mankind Pharma Details
9.20.2 Mankind Pharma Major Business
9.20.3 Mankind Pharma Oral Anti-Diabetic Drug Product and Services
9.20.4 Mankind Pharma Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.20.5 Mankind Pharma Recent Developments/Updates
9.20.6 Mankind Pharma Competitive Strengths & Weaknesses
9.21 Tonghua Dongbao
9.21.1 Tonghua Dongbao Details
9.21.2 Tonghua Dongbao Major Business
9.21.3 Tonghua Dongbao Oral Anti-Diabetic Drug Product and Services
9.21.4 Tonghua Dongbao Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.21.5 Tonghua Dongbao Recent Developments/Updates
9.21.6 Tonghua Dongbao Competitive Strengths & Weaknesses
9.22 Huadong Medicine
9.22.1 Huadong Medicine Details
9.22.2 Huadong Medicine Major Business
9.22.3 Huadong Medicine Oral Anti-Diabetic Drug Product and Services
9.22.4 Huadong Medicine Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.22.5 Huadong Medicine Recent Developments/Updates
9.22.6 Huadong Medicine Competitive Strengths & Weaknesses
9.23 CSPC Pharmaceutical Group
9.23.1 CSPC Pharmaceutical Group Details
9.23.2 CSPC Pharmaceutical Group Major Business
9.23.3 CSPC Pharmaceutical Group Oral Anti-Diabetic Drug Product and Services
9.23.4 CSPC Pharmaceutical Group Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.23.5 CSPC Pharmaceutical Group Recent Developments/Updates
9.23.6 CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
9.24 Fosun Pharma
9.24.1 Fosun Pharma Details
9.24.2 Fosun Pharma Major Business
9.24.3 Fosun Pharma Oral Anti-Diabetic Drug Product and Services
9.24.4 Fosun Pharma Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.24.5 Fosun Pharma Recent Developments/Updates
9.24.6 Fosun Pharma Competitive Strengths & Weaknesses
9.25 Qilu Pharmaceutical
9.25.1 Qilu Pharmaceutical Details
9.25.2 Qilu Pharmaceutical Major Business
9.25.3 Qilu Pharmaceutical Oral Anti-Diabetic Drug Product and Services
9.25.4 Qilu Pharmaceutical Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.25.5 Qilu Pharmaceutical Recent Developments/Updates
9.25.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Oral Anti-Diabetic Drug Industry Chain
10.2 Oral Anti-Diabetic Drug Upstream Analysis
10.2.1 Oral Anti-Diabetic Drug Core Raw Materials
10.2.2 Main Manufacturers of Oral Anti-Diabetic Drug Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Oral Anti-Diabetic Drug Production Mode
10.6 Oral Anti-Diabetic Drug Procurement Model
10.7 Oral Anti-Diabetic Drug Industry Sales Model and Sales Channels
10.7.1 Oral Anti-Diabetic Drug Sales Model
10.7.2 Oral Anti-Diabetic Drug Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Oral Anti-Diabetic Drug Introduction
1.2 World Oral Anti-Diabetic Drug Supply & Forecast
1.2.1 World Oral Anti-Diabetic Drug Production Value (2021 & 2025 & 2032)
1.2.2 World Oral Anti-Diabetic Drug Production (2021-2032)
1.2.3 World Oral Anti-Diabetic Drug Pricing Trends (2021-2032)
1.3 World Oral Anti-Diabetic Drug Production by Region (Based on Production Site)
1.3.1 World Oral Anti-Diabetic Drug Production Value by Region (2021-2032)
1.3.2 World Oral Anti-Diabetic Drug Production by Region (2021-2032)
1.3.3 World Oral Anti-Diabetic Drug Average Price by Region (2021-2032)
1.3.4 North America Oral Anti-Diabetic Drug Production (2021-2032)
1.3.5 Europe Oral Anti-Diabetic Drug Production (2021-2032)
1.3.6 China Oral Anti-Diabetic Drug Production (2021-2032)
1.3.7 Japan Oral Anti-Diabetic Drug Production (2021-2032)
1.3.8 India Oral Anti-Diabetic Drug Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oral Anti-Diabetic Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Oral Anti-Diabetic Drug Major Market Trends
2 DEMAND SUMMARY
2.1 World Oral Anti-Diabetic Drug Demand (2021-2032)
2.2 World Oral Anti-Diabetic Drug Consumption by Region
2.2.1 World Oral Anti-Diabetic Drug Consumption by Region (2021-2026)
2.2.2 World Oral Anti-Diabetic Drug Consumption Forecast by Region (2027-2032)
2.3 United States Oral Anti-Diabetic Drug Consumption (2021-2032)
2.4 China Oral Anti-Diabetic Drug Consumption (2021-2032)
2.5 Europe Oral Anti-Diabetic Drug Consumption (2021-2032)
2.6 Japan Oral Anti-Diabetic Drug Consumption (2021-2032)
2.7 South Korea Oral Anti-Diabetic Drug Consumption (2021-2032)
2.8 ASEAN Oral Anti-Diabetic Drug Consumption (2021-2032)
2.9 India Oral Anti-Diabetic Drug Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Oral Anti-Diabetic Drug Production Value by Manufacturer (2021-2026)
3.2 World Oral Anti-Diabetic Drug Production by Manufacturer (2021-2026)
3.3 World Oral Anti-Diabetic Drug Average Price by Manufacturer (2021-2026)
3.4 Oral Anti-Diabetic Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Oral Anti-Diabetic Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Oral Anti-Diabetic Drug in 2025
3.5.3 Global Concentration Ratios (CR8) for Oral Anti-Diabetic Drug in 2025
3.6 Oral Anti-Diabetic Drug Market: Overall Company Footprint Analysis
3.6.1 Oral Anti-Diabetic Drug Market: Region Footprint
3.6.2 Oral Anti-Diabetic Drug Market: Company Product Type Footprint
3.6.3 Oral Anti-Diabetic Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Oral Anti-Diabetic Drug Production Value Comparison
4.1.1 United States VS China: Oral Anti-Diabetic Drug Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Oral Anti-Diabetic Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Oral Anti-Diabetic Drug Production Comparison
4.2.1 United States VS China: Oral Anti-Diabetic Drug Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Oral Anti-Diabetic Drug Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Oral Anti-Diabetic Drug Consumption Comparison
4.3.1 United States VS China: Oral Anti-Diabetic Drug Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Oral Anti-Diabetic Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Oral Anti-Diabetic Drug Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Oral Anti-Diabetic Drug Production Value (2021-2026)
4.4.3 United States Based Manufacturers Oral Anti-Diabetic Drug Production (2021-2026)
4.5 China Based Oral Anti-Diabetic Drug Manufacturers and Market Share
4.5.1 China Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Oral Anti-Diabetic Drug Production Value (2021-2026)
4.5.3 China Based Manufacturers Oral Anti-Diabetic Drug Production (2021-2026)
4.6 Rest of World Based Oral Anti-Diabetic Drug Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Oral Anti-Diabetic Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 SGLT2 Inhibitors
5.2.2 DPP-4 Inhibitors
5.2.3 Biguanides
5.2.4 Sulfonylureas
5.2.5 Thiazolidinediones
5.2.6 Alpha-Glucosidase Inhibitors
5.2.7 Meglitinides
5.3 Market Segment by Type
5.3.1 World Oral Anti-Diabetic Drug Production by Type (2021-2032)
5.3.2 World Oral Anti-Diabetic Drug Production Value by Type (2021-2032)
5.3.3 World Oral Anti-Diabetic Drug Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY INNOVATION STATUS
6.1 World Oral Anti-Diabetic Drug Market Size Overview by Innovation Status: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Innovation Status
6.2.1 Innovative Patented Drugs
6.2.2 Patent-Expired Branded Drugs
6.2.3 Generic Drugs
6.3 Market Segment by Innovation Status
6.3.1 World Oral Anti-Diabetic Drug Production by Innovation Status (2021-2032)
6.3.2 World Oral Anti-Diabetic Drug Production Value by Innovation Status (2021-2032)
6.3.3 World Oral Anti-Diabetic Drug Average Price by Innovation Status (2021-2032)
7 MARKET ANALYSIS BY GUIDELINE POSITION
7.1 World Oral Anti-Diabetic Drug Market Size Overview by Guideline Position: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Guideline Position
7.2.1 First-Line Therapy
7.2.2 Second-Line Add-On
7.2.3 Third-Line / Rescue Therapy
7.3 Market Segment by Guideline Position
7.3.1 World Oral Anti-Diabetic Drug Production by Guideline Position (2021-2032)
7.3.2 World Oral Anti-Diabetic Drug Production Value by Guideline Position (2021-2032)
7.3.3 World Oral Anti-Diabetic Drug Average Price by Guideline Position (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Oral Anti-Diabetic Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital Pharmacies
8.2.2 Retail Pharmacies
8.2.3 Online Pharmacies
8.3 Market Segment by Application
8.3.1 World Oral Anti-Diabetic Drug Production by Application (2021-2032)
8.3.2 World Oral Anti-Diabetic Drug Production Value by Application (2021-2032)
8.3.3 World Oral Anti-Diabetic Drug Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 AstraZeneca
9.1.1 AstraZeneca Details
9.1.2 AstraZeneca Major Business
9.1.3 AstraZeneca Oral Anti-Diabetic Drug Product and Services
9.1.4 AstraZeneca Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 AstraZeneca Recent Developments/Updates
9.1.6 AstraZeneca Competitive Strengths & Weaknesses
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Details
9.2.2 Boehringer Ingelheim Major Business
9.2.3 Boehringer Ingelheim Oral Anti-Diabetic Drug Product and Services
9.2.4 Boehringer Ingelheim Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Boehringer Ingelheim Recent Developments/Updates
9.2.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.3 Eli Lilly and Company
9.3.1 Eli Lilly and Company Details
9.3.2 Eli Lilly and Company Major Business
9.3.3 Eli Lilly and Company Oral Anti-Diabetic Drug Product and Services
9.3.4 Eli Lilly and Company Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Eli Lilly and Company Recent Developments/Updates
9.3.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.4 Novo Nordisk
9.4.1 Novo Nordisk Details
9.4.2 Novo Nordisk Major Business
9.4.3 Novo Nordisk Oral Anti-Diabetic Drug Product and Services
9.4.4 Novo Nordisk Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Novo Nordisk Recent Developments/Updates
9.4.6 Novo Nordisk Competitive Strengths & Weaknesses
9.5 Merck
9.5.1 Merck Details
9.5.2 Merck Major Business
9.5.3 Merck Oral Anti-Diabetic Drug Product and Services
9.5.4 Merck Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Merck Recent Developments/Updates
9.5.6 Merck Competitive Strengths & Weaknesses
9.6 Novartis
9.6.1 Novartis Details
9.6.2 Novartis Major Business
9.6.3 Novartis Oral Anti-Diabetic Drug Product and Services
9.6.4 Novartis Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Novartis Recent Developments/Updates
9.6.6 Novartis Competitive Strengths & Weaknesses
9.7 Johnson & Johnson
9.7.1 Johnson & Johnson Details
9.7.2 Johnson & Johnson Major Business
9.7.3 Johnson & Johnson Oral Anti-Diabetic Drug Product and Services
9.7.4 Johnson & Johnson Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Johnson & Johnson Recent Developments/Updates
9.7.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.8 Takeda Pharmaceutical Company
9.8.1 Takeda Pharmaceutical Company Details
9.8.2 Takeda Pharmaceutical Company Major Business
9.8.3 Takeda Pharmaceutical Company Oral Anti-Diabetic Drug Product and Services
9.8.4 Takeda Pharmaceutical Company Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Takeda Pharmaceutical Company Recent Developments/Updates
9.8.6 Takeda Pharmaceutical Company Competitive Strengths & Weaknesses
9.9 Teva Pharmaceutical Industries
9.9.1 Teva Pharmaceutical Industries Details
9.9.2 Teva Pharmaceutical Industries Major Business
9.9.3 Teva Pharmaceutical Industries Oral Anti-Diabetic Drug Product and Services
9.9.4 Teva Pharmaceutical Industries Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Teva Pharmaceutical Industries Recent Developments/Updates
9.9.6 Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
9.10 Viatris
9.10.1 Viatris Details
9.10.2 Viatris Major Business
9.10.3 Viatris Oral Anti-Diabetic Drug Product and Services
9.10.4 Viatris Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Viatris Recent Developments/Updates
9.10.6 Viatris Competitive Strengths & Weaknesses
9.11 Sandoz
9.11.1 Sandoz Details
9.11.2 Sandoz Major Business
9.11.3 Sandoz Oral Anti-Diabetic Drug Product and Services
9.11.4 Sandoz Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Sandoz Recent Developments/Updates
9.11.6 Sandoz Competitive Strengths & Weaknesses
9.12 Sun Pharmaceutical Industries
9.12.1 Sun Pharmaceutical Industries Details
9.12.2 Sun Pharmaceutical Industries Major Business
9.12.3 Sun Pharmaceutical Industries Oral Anti-Diabetic Drug Product and Services
9.12.4 Sun Pharmaceutical Industries Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Sun Pharmaceutical Industries Recent Developments/Updates
9.12.6 Sun Pharmaceutical Industries Competitive Strengths & Weaknesses
9.13 Dr. Reddy's Laboratories
9.13.1 Dr. Reddy's Laboratories Details
9.13.2 Dr. Reddy's Laboratories Major Business
9.13.3 Dr. Reddy's Laboratories Oral Anti-Diabetic Drug Product and Services
9.13.4 Dr. Reddy's Laboratories Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Dr. Reddy's Laboratories Recent Developments/Updates
9.13.6 Dr. Reddy's Laboratories Competitive Strengths & Weaknesses
9.14 Aurobindo Pharma
9.14.1 Aurobindo Pharma Details
9.14.2 Aurobindo Pharma Major Business
9.14.3 Aurobindo Pharma Oral Anti-Diabetic Drug Product and Services
9.14.4 Aurobindo Pharma Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Aurobindo Pharma Recent Developments/Updates
9.14.6 Aurobindo Pharma Competitive Strengths & Weaknesses
9.15 Lupin Limited
9.15.1 Lupin Limited Details
9.15.2 Lupin Limited Major Business
9.15.3 Lupin Limited Oral Anti-Diabetic Drug Product and Services
9.15.4 Lupin Limited Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Lupin Limited Recent Developments/Updates
9.15.6 Lupin Limited Competitive Strengths & Weaknesses
9.16 Cipla
9.16.1 Cipla Details
9.16.2 Cipla Major Business
9.16.3 Cipla Oral Anti-Diabetic Drug Product and Services
9.16.4 Cipla Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Cipla Recent Developments/Updates
9.16.6 Cipla Competitive Strengths & Weaknesses
9.17 Torrent Pharmaceuticals
9.17.1 Torrent Pharmaceuticals Details
9.17.2 Torrent Pharmaceuticals Major Business
9.17.3 Torrent Pharmaceuticals Oral Anti-Diabetic Drug Product and Services
9.17.4 Torrent Pharmaceuticals Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 Torrent Pharmaceuticals Recent Developments/Updates
9.17.6 Torrent Pharmaceuticals Competitive Strengths & Weaknesses
9.18 Zydus Lifesciences
9.18.1 Zydus Lifesciences Details
9.18.2 Zydus Lifesciences Major Business
9.18.3 Zydus Lifesciences Oral Anti-Diabetic Drug Product and Services
9.18.4 Zydus Lifesciences Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Zydus Lifesciences Recent Developments/Updates
9.18.6 Zydus Lifesciences Competitive Strengths & Weaknesses
9.19 Abbott
9.19.1 Abbott Details
9.19.2 Abbott Major Business
9.19.3 Abbott Oral Anti-Diabetic Drug Product and Services
9.19.4 Abbott Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.19.5 Abbott Recent Developments/Updates
9.19.6 Abbott Competitive Strengths & Weaknesses
9.20 Mankind Pharma
9.20.1 Mankind Pharma Details
9.20.2 Mankind Pharma Major Business
9.20.3 Mankind Pharma Oral Anti-Diabetic Drug Product and Services
9.20.4 Mankind Pharma Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.20.5 Mankind Pharma Recent Developments/Updates
9.20.6 Mankind Pharma Competitive Strengths & Weaknesses
9.21 Tonghua Dongbao
9.21.1 Tonghua Dongbao Details
9.21.2 Tonghua Dongbao Major Business
9.21.3 Tonghua Dongbao Oral Anti-Diabetic Drug Product and Services
9.21.4 Tonghua Dongbao Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.21.5 Tonghua Dongbao Recent Developments/Updates
9.21.6 Tonghua Dongbao Competitive Strengths & Weaknesses
9.22 Huadong Medicine
9.22.1 Huadong Medicine Details
9.22.2 Huadong Medicine Major Business
9.22.3 Huadong Medicine Oral Anti-Diabetic Drug Product and Services
9.22.4 Huadong Medicine Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.22.5 Huadong Medicine Recent Developments/Updates
9.22.6 Huadong Medicine Competitive Strengths & Weaknesses
9.23 CSPC Pharmaceutical Group
9.23.1 CSPC Pharmaceutical Group Details
9.23.2 CSPC Pharmaceutical Group Major Business
9.23.3 CSPC Pharmaceutical Group Oral Anti-Diabetic Drug Product and Services
9.23.4 CSPC Pharmaceutical Group Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.23.5 CSPC Pharmaceutical Group Recent Developments/Updates
9.23.6 CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
9.24 Fosun Pharma
9.24.1 Fosun Pharma Details
9.24.2 Fosun Pharma Major Business
9.24.3 Fosun Pharma Oral Anti-Diabetic Drug Product and Services
9.24.4 Fosun Pharma Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.24.5 Fosun Pharma Recent Developments/Updates
9.24.6 Fosun Pharma Competitive Strengths & Weaknesses
9.25 Qilu Pharmaceutical
9.25.1 Qilu Pharmaceutical Details
9.25.2 Qilu Pharmaceutical Major Business
9.25.3 Qilu Pharmaceutical Oral Anti-Diabetic Drug Product and Services
9.25.4 Qilu Pharmaceutical Oral Anti-Diabetic Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.25.5 Qilu Pharmaceutical Recent Developments/Updates
9.25.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Oral Anti-Diabetic Drug Industry Chain
10.2 Oral Anti-Diabetic Drug Upstream Analysis
10.2.1 Oral Anti-Diabetic Drug Core Raw Materials
10.2.2 Main Manufacturers of Oral Anti-Diabetic Drug Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Oral Anti-Diabetic Drug Production Mode
10.6 Oral Anti-Diabetic Drug Procurement Model
10.7 Oral Anti-Diabetic Drug Industry Sales Model and Sales Channels
10.7.1 Oral Anti-Diabetic Drug Sales Model
10.7.2 Oral Anti-Diabetic Drug Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Oral Anti-Diabetic Drug Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Oral Anti-Diabetic Drug Production Value by Region (2021-2026) & (USD Million)
Table 3. World Oral Anti-Diabetic Drug Production Value by Region (2027-2032) & (USD Million)
Table 4. World Oral Anti-Diabetic Drug Production Value Market Share by Region (2021-2026)
Table 5. World Oral Anti-Diabetic Drug Production Value Market Share by Region (2027-2032)
Table 6. World Oral Anti-Diabetic Drug Production by Region (2021-2026) & (K Units)
Table 7. World Oral Anti-Diabetic Drug Production by Region (2027-2032) & (K Units)
Table 8. World Oral Anti-Diabetic Drug Production Market Share by Region (2021-2026)
Table 9. World Oral Anti-Diabetic Drug Production Market Share by Region (2027-2032)
Table 10. World Oral Anti-Diabetic Drug Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Oral Anti-Diabetic Drug Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Oral Anti-Diabetic Drug Major Market Trends
Table 13. World Oral Anti-Diabetic Drug Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Oral Anti-Diabetic Drug Consumption by Region (2021-2026) & (K Units)
Table 15. World Oral Anti-Diabetic Drug Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Oral Anti-Diabetic Drug Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Oral Anti-Diabetic Drug Producers in 2025
Table 18. World Oral Anti-Diabetic Drug Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Oral Anti-Diabetic Drug Producers in 2025
Table 20. World Oral Anti-Diabetic Drug Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Oral Anti-Diabetic Drug Company Evaluation Quadrant
Table 22. World Oral Anti-Diabetic Drug Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Oral Anti-Diabetic Drug Production Site of Key Manufacturer
Table 24. Oral Anti-Diabetic Drug Market: Company Product Type Footprint
Table 25. Oral Anti-Diabetic Drug Market: Company Product Application Footprint
Table 26. Oral Anti-Diabetic Drug Competitive Factors
Table 27. Oral Anti-Diabetic Drug New Entrant and Capacity Expansion Plans
Table 28. Oral Anti-Diabetic Drug Mergers & Acquisitions Activity
Table 29. United States VS China Oral Anti-Diabetic Drug Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Oral Anti-Diabetic Drug Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Oral Anti-Diabetic Drug Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Oral Anti-Diabetic Drug Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Oral Anti-Diabetic Drug Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Oral Anti-Diabetic Drug Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Oral Anti-Diabetic Drug Production Market Share (2021-2026)
Table 37. China Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Oral Anti-Diabetic Drug Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Oral Anti-Diabetic Drug Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Oral Anti-Diabetic Drug Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Oral Anti-Diabetic Drug Production Market Share (2021-2026)
Table 42. Rest of World Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Market Share (2021-2026)
Table 47. World Oral Anti-Diabetic Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Oral Anti-Diabetic Drug Production by Type (2021-2026) & (K Units)
Table 49. World Oral Anti-Diabetic Drug Production by Type (2027-2032) & (K Units)
Table 50. World Oral Anti-Diabetic Drug Production Value by Type (2021-2026) & (USD Million)
Table 51. World Oral Anti-Diabetic Drug Production Value by Type (2027-2032) & (USD Million)
Table 52. World Oral Anti-Diabetic Drug Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Oral Anti-Diabetic Drug Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Oral Anti-Diabetic Drug Production Value by Innovation Status, (USD Million), 2021 & 2025 & 2032
Table 55. World Oral Anti-Diabetic Drug Production by Innovation Status (2021-2026) & (K Units)
Table 56. World Oral Anti-Diabetic Drug Production by Innovation Status (2027-2032) & (K Units)
Table 57. World Oral Anti-Diabetic Drug Production Value by Innovation Status (2021-2026) & (USD Million)
Table 58. World Oral Anti-Diabetic Drug Production Value by Innovation Status (2027-2032) & (USD Million)
Table 59. World Oral Anti-Diabetic Drug Average Price by Innovation Status (2021-2026) & (US$/Unit)
Table 60. World Oral Anti-Diabetic Drug Average Price by Innovation Status (2027-2032) & (US$/Unit)
Table 61. World Oral Anti-Diabetic Drug Production Value by Guideline Position, (USD Million), 2021 & 2025 & 2032
Table 62. World Oral Anti-Diabetic Drug Production by Guideline Position (2021-2026) & (K Units)
Table 63. World Oral Anti-Diabetic Drug Production by Guideline Position (2027-2032) & (K Units)
Table 64. World Oral Anti-Diabetic Drug Production Value by Guideline Position (2021-2026) & (USD Million)
Table 65. World Oral Anti-Diabetic Drug Production Value by Guideline Position (2027-2032) & (USD Million)
Table 66. World Oral Anti-Diabetic Drug Average Price by Guideline Position (2021-2026) & (US$/Unit)
Table 67. World Oral Anti-Diabetic Drug Average Price by Guideline Position (2027-2032) & (US$/Unit)
Table 68. World Oral Anti-Diabetic Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Oral Anti-Diabetic Drug Production by Application (2021-2026) & (K Units)
Table 70. World Oral Anti-Diabetic Drug Production by Application (2027-2032) & (K Units)
Table 71. World Oral Anti-Diabetic Drug Production Value by Application (2021-2026) & (USD Million)
Table 72. World Oral Anti-Diabetic Drug Production Value by Application (2027-2032) & (USD Million)
Table 73. World Oral Anti-Diabetic Drug Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Oral Anti-Diabetic Drug Average Price by Application (2027-2032) & (US$/Unit)
Table 75. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 76. AstraZeneca Major Business
Table 77. AstraZeneca Oral Anti-Diabetic Drug Product and Services
Table 78. AstraZeneca Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. AstraZeneca Recent Developments/Updates
Table 80. AstraZeneca Competitive Strengths & Weaknesses
Table 81. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 82. Boehringer Ingelheim Major Business
Table 83. Boehringer Ingelheim Oral Anti-Diabetic Drug Product and Services
Table 84. Boehringer Ingelheim Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Boehringer Ingelheim Recent Developments/Updates
Table 86. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 87. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 88. Eli Lilly and Company Major Business
Table 89. Eli Lilly and Company Oral Anti-Diabetic Drug Product and Services
Table 90. Eli Lilly and Company Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Eli Lilly and Company Recent Developments/Updates
Table 92. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 93. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 94. Novo Nordisk Major Business
Table 95. Novo Nordisk Oral Anti-Diabetic Drug Product and Services
Table 96. Novo Nordisk Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Novo Nordisk Recent Developments/Updates
Table 98. Novo Nordisk Competitive Strengths & Weaknesses
Table 99. Merck Basic Information, Manufacturing Base and Competitors
Table 100. Merck Major Business
Table 101. Merck Oral Anti-Diabetic Drug Product and Services
Table 102. Merck Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Merck Recent Developments/Updates
Table 104. Merck Competitive Strengths & Weaknesses
Table 105. Novartis Basic Information, Manufacturing Base and Competitors
Table 106. Novartis Major Business
Table 107. Novartis Oral Anti-Diabetic Drug Product and Services
Table 108. Novartis Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Novartis Recent Developments/Updates
Table 110. Novartis Competitive Strengths & Weaknesses
Table 111. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 112. Johnson & Johnson Major Business
Table 113. Johnson & Johnson Oral Anti-Diabetic Drug Product and Services
Table 114. Johnson & Johnson Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Johnson & Johnson Recent Developments/Updates
Table 116. Johnson & Johnson Competitive Strengths & Weaknesses
Table 117. Takeda Pharmaceutical Company Basic Information, Manufacturing Base and Competitors
Table 118. Takeda Pharmaceutical Company Major Business
Table 119. Takeda Pharmaceutical Company Oral Anti-Diabetic Drug Product and Services
Table 120. Takeda Pharmaceutical Company Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Takeda Pharmaceutical Company Recent Developments/Updates
Table 122. Takeda Pharmaceutical Company Competitive Strengths & Weaknesses
Table 123. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 124. Teva Pharmaceutical Industries Major Business
Table 125. Teva Pharmaceutical Industries Oral Anti-Diabetic Drug Product and Services
Table 126. Teva Pharmaceutical Industries Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Teva Pharmaceutical Industries Recent Developments/Updates
Table 128. Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
Table 129. Viatris Basic Information, Manufacturing Base and Competitors
Table 130. Viatris Major Business
Table 131. Viatris Oral Anti-Diabetic Drug Product and Services
Table 132. Viatris Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Viatris Recent Developments/Updates
Table 134. Viatris Competitive Strengths & Weaknesses
Table 135. Sandoz Basic Information, Manufacturing Base and Competitors
Table 136. Sandoz Major Business
Table 137. Sandoz Oral Anti-Diabetic Drug Product and Services
Table 138. Sandoz Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Sandoz Recent Developments/Updates
Table 140. Sandoz Competitive Strengths & Weaknesses
Table 141. Sun Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 142. Sun Pharmaceutical Industries Major Business
Table 143. Sun Pharmaceutical Industries Oral Anti-Diabetic Drug Product and Services
Table 144. Sun Pharmaceutical Industries Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Sun Pharmaceutical Industries Recent Developments/Updates
Table 146. Sun Pharmaceutical Industries Competitive Strengths & Weaknesses
Table 147. Dr. Reddy's Laboratories Basic Information, Manufacturing Base and Competitors
Table 148. Dr. Reddy's Laboratories Major Business
Table 149. Dr. Reddy's Laboratories Oral Anti-Diabetic Drug Product and Services
Table 150. Dr. Reddy's Laboratories Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Dr. Reddy's Laboratories Recent Developments/Updates
Table 152. Dr. Reddy's Laboratories Competitive Strengths & Weaknesses
Table 153. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 154. Aurobindo Pharma Major Business
Table 155. Aurobindo Pharma Oral Anti-Diabetic Drug Product and Services
Table 156. Aurobindo Pharma Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Aurobindo Pharma Recent Developments/Updates
Table 158. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 159. Lupin Limited Basic Information, Manufacturing Base and Competitors
Table 160. Lupin Limited Major Business
Table 161. Lupin Limited Oral Anti-Diabetic Drug Product and Services
Table 162. Lupin Limited Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Lupin Limited Recent Developments/Updates
Table 164. Lupin Limited Competitive Strengths & Weaknesses
Table 165. Cipla Basic Information, Manufacturing Base and Competitors
Table 166. Cipla Major Business
Table 167. Cipla Oral Anti-Diabetic Drug Product and Services
Table 168. Cipla Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Cipla Recent Developments/Updates
Table 170. Cipla Competitive Strengths & Weaknesses
Table 171. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 172. Torrent Pharmaceuticals Major Business
Table 173. Torrent Pharmaceuticals Oral Anti-Diabetic Drug Product and Services
Table 174. Torrent Pharmaceuticals Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. Torrent Pharmaceuticals Recent Developments/Updates
Table 176. Torrent Pharmaceuticals Competitive Strengths & Weaknesses
Table 177. Zydus Lifesciences Basic Information, Manufacturing Base and Competitors
Table 178. Zydus Lifesciences Major Business
Table 179. Zydus Lifesciences Oral Anti-Diabetic Drug Product and Services
Table 180. Zydus Lifesciences Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Zydus Lifesciences Recent Developments/Updates
Table 182. Zydus Lifesciences Competitive Strengths & Weaknesses
Table 183. Abbott Basic Information, Manufacturing Base and Competitors
Table 184. Abbott Major Business
Table 185. Abbott Oral Anti-Diabetic Drug Product and Services
Table 186. Abbott Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 187. Abbott Recent Developments/Updates
Table 188. Abbott Competitive Strengths & Weaknesses
Table 189. Mankind Pharma Basic Information, Manufacturing Base and Competitors
Table 190. Mankind Pharma Major Business
Table 191. Mankind Pharma Oral Anti-Diabetic Drug Product and Services
Table 192. Mankind Pharma Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 193. Mankind Pharma Recent Developments/Updates
Table 194. Mankind Pharma Competitive Strengths & Weaknesses
Table 195. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 196. Tonghua Dongbao Major Business
Table 197. Tonghua Dongbao Oral Anti-Diabetic Drug Product and Services
Table 198. Tonghua Dongbao Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 199. Tonghua Dongbao Recent Developments/Updates
Table 200. Tonghua Dongbao Competitive Strengths & Weaknesses
Table 201. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 202. Huadong Medicine Major Business
Table 203. Huadong Medicine Oral Anti-Diabetic Drug Product and Services
Table 204. Huadong Medicine Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 205. Huadong Medicine Recent Developments/Updates
Table 206. Huadong Medicine Competitive Strengths & Weaknesses
Table 207. CSPC Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 208. CSPC Pharmaceutical Group Major Business
Table 209. CSPC Pharmaceutical Group Oral Anti-Diabetic Drug Product and Services
Table 210. CSPC Pharmaceutical Group Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 211. CSPC Pharmaceutical Group Recent Developments/Updates
Table 212. CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
Table 213. Fosun Pharma Basic Information, Manufacturing Base and Competitors
Table 214. Fosun Pharma Major Business
Table 215. Fosun Pharma Oral Anti-Diabetic Drug Product and Services
Table 216. Fosun Pharma Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 217. Fosun Pharma Recent Developments/Updates
Table 218. Fosun Pharma Competitive Strengths & Weaknesses
Table 219. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 220. Qilu Pharmaceutical Major Business
Table 221. Qilu Pharmaceutical Oral Anti-Diabetic Drug Product and Services
Table 222. Qilu Pharmaceutical Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 223. Qilu Pharmaceutical Recent Developments/Updates
Table 224. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 225. Global Key Players of Oral Anti-Diabetic Drug Upstream (Raw Materials)
Table 226. Global Oral Anti-Diabetic Drug Typical Customers
Table 227. Oral Anti-Diabetic Drug Typical Distributors
Table 1. World Oral Anti-Diabetic Drug Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Oral Anti-Diabetic Drug Production Value by Region (2021-2026) & (USD Million)
Table 3. World Oral Anti-Diabetic Drug Production Value by Region (2027-2032) & (USD Million)
Table 4. World Oral Anti-Diabetic Drug Production Value Market Share by Region (2021-2026)
Table 5. World Oral Anti-Diabetic Drug Production Value Market Share by Region (2027-2032)
Table 6. World Oral Anti-Diabetic Drug Production by Region (2021-2026) & (K Units)
Table 7. World Oral Anti-Diabetic Drug Production by Region (2027-2032) & (K Units)
Table 8. World Oral Anti-Diabetic Drug Production Market Share by Region (2021-2026)
Table 9. World Oral Anti-Diabetic Drug Production Market Share by Region (2027-2032)
Table 10. World Oral Anti-Diabetic Drug Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Oral Anti-Diabetic Drug Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Oral Anti-Diabetic Drug Major Market Trends
Table 13. World Oral Anti-Diabetic Drug Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Oral Anti-Diabetic Drug Consumption by Region (2021-2026) & (K Units)
Table 15. World Oral Anti-Diabetic Drug Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Oral Anti-Diabetic Drug Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Oral Anti-Diabetic Drug Producers in 2025
Table 18. World Oral Anti-Diabetic Drug Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Oral Anti-Diabetic Drug Producers in 2025
Table 20. World Oral Anti-Diabetic Drug Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Oral Anti-Diabetic Drug Company Evaluation Quadrant
Table 22. World Oral Anti-Diabetic Drug Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Oral Anti-Diabetic Drug Production Site of Key Manufacturer
Table 24. Oral Anti-Diabetic Drug Market: Company Product Type Footprint
Table 25. Oral Anti-Diabetic Drug Market: Company Product Application Footprint
Table 26. Oral Anti-Diabetic Drug Competitive Factors
Table 27. Oral Anti-Diabetic Drug New Entrant and Capacity Expansion Plans
Table 28. Oral Anti-Diabetic Drug Mergers & Acquisitions Activity
Table 29. United States VS China Oral Anti-Diabetic Drug Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Oral Anti-Diabetic Drug Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Oral Anti-Diabetic Drug Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Oral Anti-Diabetic Drug Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Oral Anti-Diabetic Drug Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Oral Anti-Diabetic Drug Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Oral Anti-Diabetic Drug Production Market Share (2021-2026)
Table 37. China Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Oral Anti-Diabetic Drug Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Oral Anti-Diabetic Drug Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Oral Anti-Diabetic Drug Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Oral Anti-Diabetic Drug Production Market Share (2021-2026)
Table 42. Rest of World Based Oral Anti-Diabetic Drug Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Market Share (2021-2026)
Table 47. World Oral Anti-Diabetic Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Oral Anti-Diabetic Drug Production by Type (2021-2026) & (K Units)
Table 49. World Oral Anti-Diabetic Drug Production by Type (2027-2032) & (K Units)
Table 50. World Oral Anti-Diabetic Drug Production Value by Type (2021-2026) & (USD Million)
Table 51. World Oral Anti-Diabetic Drug Production Value by Type (2027-2032) & (USD Million)
Table 52. World Oral Anti-Diabetic Drug Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Oral Anti-Diabetic Drug Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Oral Anti-Diabetic Drug Production Value by Innovation Status, (USD Million), 2021 & 2025 & 2032
Table 55. World Oral Anti-Diabetic Drug Production by Innovation Status (2021-2026) & (K Units)
Table 56. World Oral Anti-Diabetic Drug Production by Innovation Status (2027-2032) & (K Units)
Table 57. World Oral Anti-Diabetic Drug Production Value by Innovation Status (2021-2026) & (USD Million)
Table 58. World Oral Anti-Diabetic Drug Production Value by Innovation Status (2027-2032) & (USD Million)
Table 59. World Oral Anti-Diabetic Drug Average Price by Innovation Status (2021-2026) & (US$/Unit)
Table 60. World Oral Anti-Diabetic Drug Average Price by Innovation Status (2027-2032) & (US$/Unit)
Table 61. World Oral Anti-Diabetic Drug Production Value by Guideline Position, (USD Million), 2021 & 2025 & 2032
Table 62. World Oral Anti-Diabetic Drug Production by Guideline Position (2021-2026) & (K Units)
Table 63. World Oral Anti-Diabetic Drug Production by Guideline Position (2027-2032) & (K Units)
Table 64. World Oral Anti-Diabetic Drug Production Value by Guideline Position (2021-2026) & (USD Million)
Table 65. World Oral Anti-Diabetic Drug Production Value by Guideline Position (2027-2032) & (USD Million)
Table 66. World Oral Anti-Diabetic Drug Average Price by Guideline Position (2021-2026) & (US$/Unit)
Table 67. World Oral Anti-Diabetic Drug Average Price by Guideline Position (2027-2032) & (US$/Unit)
Table 68. World Oral Anti-Diabetic Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Oral Anti-Diabetic Drug Production by Application (2021-2026) & (K Units)
Table 70. World Oral Anti-Diabetic Drug Production by Application (2027-2032) & (K Units)
Table 71. World Oral Anti-Diabetic Drug Production Value by Application (2021-2026) & (USD Million)
Table 72. World Oral Anti-Diabetic Drug Production Value by Application (2027-2032) & (USD Million)
Table 73. World Oral Anti-Diabetic Drug Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Oral Anti-Diabetic Drug Average Price by Application (2027-2032) & (US$/Unit)
Table 75. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 76. AstraZeneca Major Business
Table 77. AstraZeneca Oral Anti-Diabetic Drug Product and Services
Table 78. AstraZeneca Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. AstraZeneca Recent Developments/Updates
Table 80. AstraZeneca Competitive Strengths & Weaknesses
Table 81. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 82. Boehringer Ingelheim Major Business
Table 83. Boehringer Ingelheim Oral Anti-Diabetic Drug Product and Services
Table 84. Boehringer Ingelheim Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Boehringer Ingelheim Recent Developments/Updates
Table 86. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 87. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 88. Eli Lilly and Company Major Business
Table 89. Eli Lilly and Company Oral Anti-Diabetic Drug Product and Services
Table 90. Eli Lilly and Company Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Eli Lilly and Company Recent Developments/Updates
Table 92. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 93. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 94. Novo Nordisk Major Business
Table 95. Novo Nordisk Oral Anti-Diabetic Drug Product and Services
Table 96. Novo Nordisk Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Novo Nordisk Recent Developments/Updates
Table 98. Novo Nordisk Competitive Strengths & Weaknesses
Table 99. Merck Basic Information, Manufacturing Base and Competitors
Table 100. Merck Major Business
Table 101. Merck Oral Anti-Diabetic Drug Product and Services
Table 102. Merck Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Merck Recent Developments/Updates
Table 104. Merck Competitive Strengths & Weaknesses
Table 105. Novartis Basic Information, Manufacturing Base and Competitors
Table 106. Novartis Major Business
Table 107. Novartis Oral Anti-Diabetic Drug Product and Services
Table 108. Novartis Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Novartis Recent Developments/Updates
Table 110. Novartis Competitive Strengths & Weaknesses
Table 111. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 112. Johnson & Johnson Major Business
Table 113. Johnson & Johnson Oral Anti-Diabetic Drug Product and Services
Table 114. Johnson & Johnson Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Johnson & Johnson Recent Developments/Updates
Table 116. Johnson & Johnson Competitive Strengths & Weaknesses
Table 117. Takeda Pharmaceutical Company Basic Information, Manufacturing Base and Competitors
Table 118. Takeda Pharmaceutical Company Major Business
Table 119. Takeda Pharmaceutical Company Oral Anti-Diabetic Drug Product and Services
Table 120. Takeda Pharmaceutical Company Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Takeda Pharmaceutical Company Recent Developments/Updates
Table 122. Takeda Pharmaceutical Company Competitive Strengths & Weaknesses
Table 123. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 124. Teva Pharmaceutical Industries Major Business
Table 125. Teva Pharmaceutical Industries Oral Anti-Diabetic Drug Product and Services
Table 126. Teva Pharmaceutical Industries Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Teva Pharmaceutical Industries Recent Developments/Updates
Table 128. Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
Table 129. Viatris Basic Information, Manufacturing Base and Competitors
Table 130. Viatris Major Business
Table 131. Viatris Oral Anti-Diabetic Drug Product and Services
Table 132. Viatris Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Viatris Recent Developments/Updates
Table 134. Viatris Competitive Strengths & Weaknesses
Table 135. Sandoz Basic Information, Manufacturing Base and Competitors
Table 136. Sandoz Major Business
Table 137. Sandoz Oral Anti-Diabetic Drug Product and Services
Table 138. Sandoz Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Sandoz Recent Developments/Updates
Table 140. Sandoz Competitive Strengths & Weaknesses
Table 141. Sun Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 142. Sun Pharmaceutical Industries Major Business
Table 143. Sun Pharmaceutical Industries Oral Anti-Diabetic Drug Product and Services
Table 144. Sun Pharmaceutical Industries Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Sun Pharmaceutical Industries Recent Developments/Updates
Table 146. Sun Pharmaceutical Industries Competitive Strengths & Weaknesses
Table 147. Dr. Reddy's Laboratories Basic Information, Manufacturing Base and Competitors
Table 148. Dr. Reddy's Laboratories Major Business
Table 149. Dr. Reddy's Laboratories Oral Anti-Diabetic Drug Product and Services
Table 150. Dr. Reddy's Laboratories Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Dr. Reddy's Laboratories Recent Developments/Updates
Table 152. Dr. Reddy's Laboratories Competitive Strengths & Weaknesses
Table 153. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 154. Aurobindo Pharma Major Business
Table 155. Aurobindo Pharma Oral Anti-Diabetic Drug Product and Services
Table 156. Aurobindo Pharma Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Aurobindo Pharma Recent Developments/Updates
Table 158. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 159. Lupin Limited Basic Information, Manufacturing Base and Competitors
Table 160. Lupin Limited Major Business
Table 161. Lupin Limited Oral Anti-Diabetic Drug Product and Services
Table 162. Lupin Limited Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Lupin Limited Recent Developments/Updates
Table 164. Lupin Limited Competitive Strengths & Weaknesses
Table 165. Cipla Basic Information, Manufacturing Base and Competitors
Table 166. Cipla Major Business
Table 167. Cipla Oral Anti-Diabetic Drug Product and Services
Table 168. Cipla Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Cipla Recent Developments/Updates
Table 170. Cipla Competitive Strengths & Weaknesses
Table 171. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 172. Torrent Pharmaceuticals Major Business
Table 173. Torrent Pharmaceuticals Oral Anti-Diabetic Drug Product and Services
Table 174. Torrent Pharmaceuticals Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. Torrent Pharmaceuticals Recent Developments/Updates
Table 176. Torrent Pharmaceuticals Competitive Strengths & Weaknesses
Table 177. Zydus Lifesciences Basic Information, Manufacturing Base and Competitors
Table 178. Zydus Lifesciences Major Business
Table 179. Zydus Lifesciences Oral Anti-Diabetic Drug Product and Services
Table 180. Zydus Lifesciences Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Zydus Lifesciences Recent Developments/Updates
Table 182. Zydus Lifesciences Competitive Strengths & Weaknesses
Table 183. Abbott Basic Information, Manufacturing Base and Competitors
Table 184. Abbott Major Business
Table 185. Abbott Oral Anti-Diabetic Drug Product and Services
Table 186. Abbott Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 187. Abbott Recent Developments/Updates
Table 188. Abbott Competitive Strengths & Weaknesses
Table 189. Mankind Pharma Basic Information, Manufacturing Base and Competitors
Table 190. Mankind Pharma Major Business
Table 191. Mankind Pharma Oral Anti-Diabetic Drug Product and Services
Table 192. Mankind Pharma Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 193. Mankind Pharma Recent Developments/Updates
Table 194. Mankind Pharma Competitive Strengths & Weaknesses
Table 195. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 196. Tonghua Dongbao Major Business
Table 197. Tonghua Dongbao Oral Anti-Diabetic Drug Product and Services
Table 198. Tonghua Dongbao Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 199. Tonghua Dongbao Recent Developments/Updates
Table 200. Tonghua Dongbao Competitive Strengths & Weaknesses
Table 201. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 202. Huadong Medicine Major Business
Table 203. Huadong Medicine Oral Anti-Diabetic Drug Product and Services
Table 204. Huadong Medicine Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 205. Huadong Medicine Recent Developments/Updates
Table 206. Huadong Medicine Competitive Strengths & Weaknesses
Table 207. CSPC Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 208. CSPC Pharmaceutical Group Major Business
Table 209. CSPC Pharmaceutical Group Oral Anti-Diabetic Drug Product and Services
Table 210. CSPC Pharmaceutical Group Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 211. CSPC Pharmaceutical Group Recent Developments/Updates
Table 212. CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
Table 213. Fosun Pharma Basic Information, Manufacturing Base and Competitors
Table 214. Fosun Pharma Major Business
Table 215. Fosun Pharma Oral Anti-Diabetic Drug Product and Services
Table 216. Fosun Pharma Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 217. Fosun Pharma Recent Developments/Updates
Table 218. Fosun Pharma Competitive Strengths & Weaknesses
Table 219. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 220. Qilu Pharmaceutical Major Business
Table 221. Qilu Pharmaceutical Oral Anti-Diabetic Drug Product and Services
Table 222. Qilu Pharmaceutical Oral Anti-Diabetic Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 223. Qilu Pharmaceutical Recent Developments/Updates
Table 224. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 225. Global Key Players of Oral Anti-Diabetic Drug Upstream (Raw Materials)
Table 226. Global Oral Anti-Diabetic Drug Typical Customers
Table 227. Oral Anti-Diabetic Drug Typical Distributors
LIST OF FIGURES
Figure 1. Oral Anti-Diabetic Drug Picture
Figure 2. World Oral Anti-Diabetic Drug Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Oral Anti-Diabetic Drug Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 5. World Oral Anti-Diabetic Drug Average Price (2021-2032) & (US$/Unit)
Figure 6. World Oral Anti-Diabetic Drug Production Value Market Share by Region (2021-2032)
Figure 7. World Oral Anti-Diabetic Drug Production Market Share by Region (2021-2032)
Figure 8. North America Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 9. Europe Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 10. China Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 11. Japan Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 12. India Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 13. Oral Anti-Diabetic Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 16. World Oral Anti-Diabetic Drug Consumption Market Share by Region (2021-2032)
Figure 17. United States Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 18. China Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 19. Europe Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 20. Japan Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 21. South Korea Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 22. ASEAN Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 23. India Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 24. Producer Shipments of Oral Anti-Diabetic Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oral Anti-Diabetic Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oral Anti-Diabetic Drug Markets in 2025
Figure 27. United States VS China: Oral Anti-Diabetic Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Oral Anti-Diabetic Drug Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Oral Anti-Diabetic Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Oral Anti-Diabetic Drug Production Market Share 2025
Figure 31. China Based Manufacturers Oral Anti-Diabetic Drug Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Market Share 2025
Figure 33. World Oral Anti-Diabetic Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Oral Anti-Diabetic Drug Production Value Market Share by Type in 2025
Figure 35. SGLT2 Inhibitors
Figure 36. DPP-4 Inhibitors
Figure 37. Biguanides
Figure 38. Sulfonylureas
Figure 39. Thiazolidinediones
Figure 40. Alpha-Glucosidase Inhibitors
Figure 41. Meglitinides
Figure 42. Meglitinides
Figure 43. World Oral Anti-Diabetic Drug Production Market Share by Type (2021-2032)
Figure 44. World Oral Anti-Diabetic Drug Production Value Market Share by Type (2021-2032)
Figure 45. World Oral Anti-Diabetic Drug Average Price by Type (2021-2032) & (US$/Unit)
Figure 46. World Oral Anti-Diabetic Drug Production Value by Innovation Status, (USD Million), 2021 & 2025 & 2032
Figure 47. World Oral Anti-Diabetic Drug Production Value Market Share by Innovation Status in 2025
Figure 48. Innovative Patented Drugs
Figure 49. Patent-Expired Branded Drugs
Figure 50. Generic Drugs
Figure 51. World Oral Anti-Diabetic Drug Production Market Share by Innovation Status (2021-2032)
Figure 52. World Oral Anti-Diabetic Drug Production Value Market Share by Innovation Status (2021-2032)
Figure 53. World Oral Anti-Diabetic Drug Average Price by Innovation Status (2021-2032) & (US$/Unit)
Figure 54. World Oral Anti-Diabetic Drug Production Value by Guideline Position, (USD Million), 2021 & 2025 & 2032
Figure 55. World Oral Anti-Diabetic Drug Production Value Market Share by Guideline Position in 2025
Figure 56. First-Line Therapy
Figure 57. Second-Line Add-On
Figure 58. Third-Line / Rescue Therapy
Figure 59. World Oral Anti-Diabetic Drug Production Market Share by Guideline Position (2021-2032)
Figure 60. World Oral Anti-Diabetic Drug Production Value Market Share by Guideline Position (2021-2032)
Figure 61. World Oral Anti-Diabetic Drug Average Price by Guideline Position (2021-2032) & (US$/Unit)
Figure 62. World Oral Anti-Diabetic Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 63. World Oral Anti-Diabetic Drug Production Value Market Share by Application in 2025
Figure 64. Hospital Pharmacies
Figure 65. Retail Pharmacies
Figure 66. Online Pharmacies
Figure 67. World Oral Anti-Diabetic Drug Production Market Share by Application (2021-2032)
Figure 68. World Oral Anti-Diabetic Drug Production Value Market Share by Application (2021-2032)
Figure 69. World Oral Anti-Diabetic Drug Average Price by Application (2021-2032) & (US$/Unit)
Figure 70. Oral Anti-Diabetic Drug Industry Chain
Figure 71. Oral Anti-Diabetic Drug Procurement Model
Figure 72. Oral Anti-Diabetic Drug Sales Model
Figure 73. Oral Anti-Diabetic Drug Sales Channels, Direct Sales, and Distribution
Figure 74. Methodology
Figure 75. Research Process and Data Source
Figure 1. Oral Anti-Diabetic Drug Picture
Figure 2. World Oral Anti-Diabetic Drug Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Oral Anti-Diabetic Drug Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 5. World Oral Anti-Diabetic Drug Average Price (2021-2032) & (US$/Unit)
Figure 6. World Oral Anti-Diabetic Drug Production Value Market Share by Region (2021-2032)
Figure 7. World Oral Anti-Diabetic Drug Production Market Share by Region (2021-2032)
Figure 8. North America Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 9. Europe Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 10. China Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 11. Japan Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 12. India Oral Anti-Diabetic Drug Production (2021-2032) & (K Units)
Figure 13. Oral Anti-Diabetic Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 16. World Oral Anti-Diabetic Drug Consumption Market Share by Region (2021-2032)
Figure 17. United States Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 18. China Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 19. Europe Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 20. Japan Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 21. South Korea Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 22. ASEAN Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 23. India Oral Anti-Diabetic Drug Consumption (2021-2032) & (K Units)
Figure 24. Producer Shipments of Oral Anti-Diabetic Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oral Anti-Diabetic Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oral Anti-Diabetic Drug Markets in 2025
Figure 27. United States VS China: Oral Anti-Diabetic Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Oral Anti-Diabetic Drug Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Oral Anti-Diabetic Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Oral Anti-Diabetic Drug Production Market Share 2025
Figure 31. China Based Manufacturers Oral Anti-Diabetic Drug Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Oral Anti-Diabetic Drug Production Market Share 2025
Figure 33. World Oral Anti-Diabetic Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Oral Anti-Diabetic Drug Production Value Market Share by Type in 2025
Figure 35. SGLT2 Inhibitors
Figure 36. DPP-4 Inhibitors
Figure 37. Biguanides
Figure 38. Sulfonylureas
Figure 39. Thiazolidinediones
Figure 40. Alpha-Glucosidase Inhibitors
Figure 41. Meglitinides
Figure 42. Meglitinides
Figure 43. World Oral Anti-Diabetic Drug Production Market Share by Type (2021-2032)
Figure 44. World Oral Anti-Diabetic Drug Production Value Market Share by Type (2021-2032)
Figure 45. World Oral Anti-Diabetic Drug Average Price by Type (2021-2032) & (US$/Unit)
Figure 46. World Oral Anti-Diabetic Drug Production Value by Innovation Status, (USD Million), 2021 & 2025 & 2032
Figure 47. World Oral Anti-Diabetic Drug Production Value Market Share by Innovation Status in 2025
Figure 48. Innovative Patented Drugs
Figure 49. Patent-Expired Branded Drugs
Figure 50. Generic Drugs
Figure 51. World Oral Anti-Diabetic Drug Production Market Share by Innovation Status (2021-2032)
Figure 52. World Oral Anti-Diabetic Drug Production Value Market Share by Innovation Status (2021-2032)
Figure 53. World Oral Anti-Diabetic Drug Average Price by Innovation Status (2021-2032) & (US$/Unit)
Figure 54. World Oral Anti-Diabetic Drug Production Value by Guideline Position, (USD Million), 2021 & 2025 & 2032
Figure 55. World Oral Anti-Diabetic Drug Production Value Market Share by Guideline Position in 2025
Figure 56. First-Line Therapy
Figure 57. Second-Line Add-On
Figure 58. Third-Line / Rescue Therapy
Figure 59. World Oral Anti-Diabetic Drug Production Market Share by Guideline Position (2021-2032)
Figure 60. World Oral Anti-Diabetic Drug Production Value Market Share by Guideline Position (2021-2032)
Figure 61. World Oral Anti-Diabetic Drug Average Price by Guideline Position (2021-2032) & (US$/Unit)
Figure 62. World Oral Anti-Diabetic Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 63. World Oral Anti-Diabetic Drug Production Value Market Share by Application in 2025
Figure 64. Hospital Pharmacies
Figure 65. Retail Pharmacies
Figure 66. Online Pharmacies
Figure 67. World Oral Anti-Diabetic Drug Production Market Share by Application (2021-2032)
Figure 68. World Oral Anti-Diabetic Drug Production Value Market Share by Application (2021-2032)
Figure 69. World Oral Anti-Diabetic Drug Average Price by Application (2021-2032) & (US$/Unit)
Figure 70. Oral Anti-Diabetic Drug Industry Chain
Figure 71. Oral Anti-Diabetic Drug Procurement Model
Figure 72. Oral Anti-Diabetic Drug Sales Model
Figure 73. Oral Anti-Diabetic Drug Sales Channels, Direct Sales, and Distribution
Figure 74. Methodology
Figure 75. Research Process and Data Source
